PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29847765
OWN - NLM
STAT- MEDLINE
DCOM- 20180601
LR  - 20180604
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 22
DP  - 2018 May 31
TI  - Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.
PG  - 2141-2144
LID - 10.1056/NEJMc1805135 [doi]
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Sulfonamides)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - N54AIC43PW (venetoclax)
SB  - AIM
SB  - IM
CON - N Engl J Med. ;378(22):2141-2. PMID: 29847897
CON - N Engl J Med. ;378(22):2142-3. PMID: 29847898
MH  - Antineoplastic Agents
MH  - Bridged Bicyclo Compounds, Heterocyclic
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell
MH  - *Rituximab
MH  - Sulfonamides
EDAT- 2018/05/31 06:00
MHDA- 2018/06/02 06:00
CRDT- 2018/05/31 06:00
PHST- 2018/05/31 06:00 [entrez]
PHST- 2018/05/31 06:00 [pubmed]
PHST- 2018/06/02 06:00 [medline]
AID - 10.1056/NEJMc1805135 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 May 31;378(22):2141-2144. doi: 10.1056/NEJMc1805135.